- Home
- PIII vs MYNZ Comparison
PIII vs MYNZ Comparison
Compare PIII & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PIII | MYNZ |
|---|---|---|
| Founded | 2015 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 10.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PIII | MYNZ |
|---|---|---|
| Price | $1.65 | $1.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $16.25 | $14.00 |
| AVG Volume (30 Days) | 19.8K | ★ 588.0K |
| Earning Date | 11-13-2025 | 09-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,444,952,000.00 | $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.85 | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.75 | $0.92 |
| 52 Week High | $12.45 | $8.20 |
Technical Indicators
Market Signals| Indicator | PIII | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 20.17 | 50.40 |
| Support Level | $2.54 | $1.15 |
| Resistance Level | $2.63 | $1.37 |
| Average True Range (ATR) | 0.40 | 0.13 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 13.86 | 22.12 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.